The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Authorised psychiatrists can access products containing 3,4‑methylenedioxy‑methamphetamine (MDMA) or psilocybine for specific mental health conditions from 1 July 2023.
MDMA can be used for the treatment of post-traumatic stress disorder.
Psilocybine can be used for treatment-resistant depression.
To access products containing MDMA or psilocybine, you must be a registered psychiatrist approved under the TGA's Authorised Prescriber scheme.